Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of May 21, 2026, ACAD trades at $20.95 with a market cap of $3.54B and a P/E ratio of 9.34. ACAD moved +2.25% today. Year to date, ACAD is -19.89%; over the trailing twelve months it is -3.41%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is strong buy with an average price target of $32.77. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading ACAD stock inside the company?
Recent ACAD insider activity includes Kihara James sold 1.33K, Schneyer Mark C. sold 3.51K, Schneyer Mark C. sold 2.71K, Kihara James sold 1.03K, and Kihara James sold 1.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
ACAD Key Metrics
Key financial metrics for ACAD
Metric
Value
Price
$20.95
Market Cap
$3.54B
P/E Ratio
9.34
EPS
$2.23
Dividend Yield
0.00%
52-Week High
$28.35
52-Week Low
$13.40
Volume
0
Avg Volume
0
Revenue (TTM)
$1.10B
Net Income
$375.65M
Gross Margin
91.47%
Recent ACAD Insider Trades
Kihara James sold 1.33K (~$29.02K) on May 4, 2026.
Schneyer Mark C. sold 3.51K (~$76.40K) on May 4, 2026.
Schneyer Mark C. sold 2.71K (~$60.14K) on Apr 7, 2026.
Kihara James sold 1.03K (~$22.87K) on Apr 7, 2026.
Kihara James sold 1.10K (~$23.75K) on Mar 26, 2026.
Recent ACAD insider activity includes Kihara James sold 1.33K, Schneyer Mark C. sold 3.51K, Schneyer Mark C. sold 2.71K, Kihara James sold 1.03K, and Kihara James sold 1.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ACAD?
Yes. Rallies tracks ACAD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ACAD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ACAD. It does not provide personalized investment advice.
